Dates: March 17-21, 2026
Location: Copenhagen, Denmark
Organizer: Kenes Group
Overview
Mermaid diagram (expand to render)
Blood biomarkers emerged as a major focus at AD/PD 2026, with significant advances in both Alzheimer's disease and Parkinson's disease diagnostics and disease tracking. The shift from cerebrospinal fluid (CSF) to blood-based biomarkers promises to revolutionize early diagnosis and clinical trial design["@hansson2024"]. This conference marked a pivotal moment in the field, with multiple presentations detailing the transition from research validation to clinical implementation. Over 600 presentations addressed blood-based biomarkers across both AD and PD, reflecting the rapid maturation of this field.
The 2026 AD/PD conference showcased the most comprehensive blood biomarker data to date, with multi-center validation studies, health economic analyses, and implementation strategies presented across both Alzheimer's and Parkinson's disease tracks. The integration of blood biomarkers into clinical practice is no longer a distant goal but an imminent reality, with regulatory submissions pending for multiple diagnostic assays.
Alzheimer's Disease Blood Biomarkers
Phosphorylated Tau (p-tau) Biomarkers
The phosphorylated tau biomarkers represent the most significant advance in AD blood testing, with multiple epitopes now validated for clinical use.
p-tau217
The most advanced blood biomarker for AD showed exceptional performance:
- Discrimination accuracy: AUC 0.95-0.97 for distinguishing AD from other neurodegenerative conditions, outperforming all other blood biomarkers[@sunderland2024]
- Correlation with amyloid: Strong correlation (r = 0.7-0.8) with PET amyloid burden across multiple cohorts
- Longitudinal changes: Tracks disease progression over time, with annual increases of 8-12% in converters from MCI to AD
- Clinical utility: Suitable for primary care screening, with point-of-care platforms in development
- Platform availability: Available on Roche, Fujirebio, and Simoa platforms, with FDA submission expected in 2026
The p-tau217 biomarker has emerged as the leading blood-based test for AD pathology detection. Phosphorylation at threonine 217 occurs early in the disease process and correlates strongly with both amyloid and tau pathology on PET imaging. Studies from multiple large consortia, including the Alzheimer's Disease Neuroimaging Initiative (ADNI) and the Swedish BioFINDER cohort, have validated these findings across diverse populations.
p-tau181
- Widely validated: Multiple independent cohorts including over 10,000 participants
- Detection threshold: Can detect amyloid positivity before clinical symptoms, with 85% sensitivity in preclinical AD
- Platform comparisons: Simoa, Lumipulse, and mass spectrometry approaches all show robust performance
- Clinical availability: Most widely available p-tau assay, with FDA-cleared tests already in use
While p-tau217 shows slightly superior performance, p-tau181 remains clinically valuable due to broader assay availability and established clinical experience[@schindler2024]. The biomarker provides reliable detection of AD pathology and is particularly useful for population-based screening programs.
p-tau231
- Early detection: Changes occur before p-tau181 in the disease course, potentially 5-10 years earlier
- Specificity: Highly specific for AD pathology, with less elevation in other tauopathies
- Combination potential: Best used in combination with other markers for comprehensive assessment
- Research status: Primarily available in research settings, clinical implementation pending
The p-tau231 epitope shows particular promise for identifying individuals in the earliest disease stages, before significant cognitive symptoms emerge. Studies demonstrate that p-tau231 elevation precedes p-tau181 elevation by approximately 2-5 years in the typical AD disease course[@janelidze2024].
Amyloid Biomarkers
Plasma Aβ42/Aβ40 Ratio
- Reduced ratio: Reflects brain amyloid deposition, with approximately 30-40% reduction in AD patients
- FDA-approved assays: Commercial platforms now available from Roche and Fujirebio
- Clinical implementation: Used in specialty clinics with appropriate expertise
- Limitations: Lower sensitivity than p-tau for early detection, requires careful interpretation
The plasma Aβ42/Aβ40 ratio provides direct information about amyloid pathology, complementing the tau-focused p-tau biomarkers. Studies demonstrate that the ratio has reasonable accuracy for detecting significant amyloid burden, though performance is somewhat lower than p-tau217[@gupta2024].
Aβ Oligomers
- Toxic species detection: Targeting soluble oligomers rather than plaque burden
- Correlation with cognition: Better correlation than plaque measures with cognitive performance
- Therapeutic monitoring: Potential for treatment response tracking
- Research status: Currently available primarily in research settings
The detection of soluble Aβ oligomers represents the next frontier in amyloid biomarker development. These species are thought to be the most toxic form of amyloid and may provide superior correlation with clinical outcomes compared to plaque-based measures.
Neurodegeneration Markers
Neurofilament Light Chain (NfL)
- Marker of neuronal injury: Elevated in AD progression, with levels correlating with disease severity
- Rate of change: Faster increase predicts more rapid cognitive decline
- Cross-disease relevance: Also elevated in PD and other disorders, limiting disease specificity
- Treatment response: Sensitive to disease-modifying effects, enabling treatment monitoring
NfL provides a general marker of neuroaxonal injury that complements disease-specific biomarkers. The biomarker is elevated across neurodegenerative conditions, making it most useful for tracking disease progression rather than establishing diagnosis[@khalil2024].
Neurogranin
- Synaptic damage marker: Specific to synaptic degeneration in AD
- Cognitive correlation: Associates with cognitive performance measures
- Diagnostic utility: Helps differentiate AD from other dementias
- Clinical availability: Increasingly available on automated platforms
Synaptic loss is a key feature of AD pathophysiology, and neurogranin provides a blood-based window into this process. The biomarker shows elevated levels in AD compared to other dementias, providing complementary diagnostic information.
Glial Fibrillary Acidic Protein (GFAP)
- Astrocyte activation marker: Reflects astrocytic response to neurodegeneration
- AD specificity: More elevated in AD than in other neurodegenerative conditions
- Progression tracking: Changes correlate with disease progression rate
- Combination value: Enhanced diagnostic performance when combined with p-tau
GFAP has emerged as a key marker of the astrocytic response in AD, providing information that complements tau and neurodegeneration markers. Studies demonstrate that GFAP in combination with p-tau217 achieves AUC values above 0.97 for AD detection[@pichet2024].
Parkinson's Disease Blood Biomarkers
Alpha-Synuclein Assays
Alpha-synuclein blood biomarkers represent a major focus for PD research, with seed amplification assays showing particular promise.
Seed Amplification Assays (SAAs)
- RT-QuIC and PMCA: Detecting pathological alpha-synuclein aggregates in biological samples
- Sensitivity: Can detect prodromal PD in individuals with REM sleep behavior disorder
- Specificity: High specificity (90-95%) for distinguishing synucleinopathies from controls
- Clinical use: Moving toward clinical implementation, with CLIA-certified assays in development
Seed amplification assays leverage the prion-like properties of pathological alpha-synuclein to detect extremely low levels of misfolded protein. These assays have demonstrated the ability to detect alpha-synuclein pathology in CSF and other biological samples with unprecedented sensitivity[@thompson2024].
Total Alpha-Synuclein
- Reduced levels: Lower in PD CSF and blood compared to controls
- Diagnostic potential: Helps differentiate PD from other movement disorders
- Limitations: Less specific than SAAs, with significant overlap between disease groups
- Technical challenges: Assay standardization remains challenging across platforms
Total alpha-synuclein measurements provide a simpler approach than seed amplification, though with lower diagnostic specificity. The reduced levels in PD likely reflect decreased secretion from affected neurons.
p-Ser129 Alpha-Synuclein
- Pathological form: Detects phosphorylated alpha-synuclein, the major constituent of Lewy bodies
- Diagnostic utility: High sensitivity for established PD
- Disease progression: Levels correlate with disease severity and progression
- Sample types: Measurable in blood, CSF, and tissue samples
The detection of phosphorylated alpha-synuclein provides direct evidence of Lewy body pathology. Studies demonstrate that p-Ser129 levels are elevated in the majority of PD patients and correlate with clinical measures of disease severity.
Neurodegeneration Markers in PD
NfL in Parkinson's
- Progression marker: Higher levels with disease progression and advanced stages
- Cognitive decline: Predicts development of PD dementia
- Treatment monitoring: Sensitive to dopaminergic therapy effects
- Prognostic value: Higher baseline levels predict faster progression
NfL in PD demonstrates similar patterns to other neurodegenerative conditions, with elevations reflecting ongoing neuronal injury. The biomarker provides prognostic information and can track disease progression over time[@chen2024].
Tau in Parkinson's
- Hyperphosphorylated tau: Elevated in PD with dementia
- 4R-tau: Specific isoform in progressive supranuclear palsy and CBD
- Differential diagnosis: Helps distinguish parkinsonian disorders
Tau biomarkers provide important information in PD, particularly for patients with atypical presentations. The distinction between PD and 4R tauopathies such as PSP and CBD has important prognostic and therapeutic implications.
Cross-Disease Biomarkers
Inflammation Markers
Microglial Activation
- YKL-40 (Chitinase-3-like 1): Elevated in both AD and PD, reflecting neuroinflammation
- sTREM2: Soluble TREM2 fragment, reflecting microglial activation status
- GFAP: Astrocyte activation marker elevated in AD
Neuroinflammation is a common feature of neurodegenerative diseases, and biomarker approaches to quantify this response are actively being developed. YKL-40 and sTREM2 provide complementary information about microglial activation, while GFAP reflects astrocytic responses[@poston2024].
Systemic Inflammation
- IL-6: Pro-inflammatory cytokine with associations to neurodegeneration
- CRP: C-reactive protein, elevated in some PD patients
- TNF-alpha: Tumor necrosis factor alpha, elevated in AD and PD
Systemic inflammatory markers show associations with neurodegeneration, though their clinical utility remains to be established. These markers may provide information about inflammatory processes contributing to disease pathogenesis.
Neurotrophic Factors
- BDNF: Brain-derived neurotrophic factor, reduced in AD and PD
- GDNF: Glial cell line-derived neurotrophic factor, important for dopaminergic neurons
- NGF: Nerve growth factor, altered in neurodegenerative conditions
Neurotrophic factor measurements provide information about the brain's repair and resilience mechanisms. While currently primarily research tools, these biomarkers may eventually inform therapeutic strategies.
Technical Advances
Ultrasensitive Assays
Single Molecule Array (Simoa)
- Femtomolar sensitivity: Detecting extremely low concentrations of biomarkers
- Multiplexing: Multiple biomarkers from single sample
- Automation: High-throughput clinical laboratory implementation
Simoa technology has revolutionized blood-based biomarker detection, enabling measurement of proteins at concentrations previously only detectable in CSF. This technological advance has been essential for the development of blood-based neurodegenerative disease biomarkers.
Mass Spectrometry
- Precise quantification: Accurate measurement of peptide levels
- Post-translational modifications: Can detect phosphorylated species
- Standardization: Reference methods for calibration across platforms
Mass spectrometry approaches provide precise, specific measurements that complement immunoassay-based approaches. These methods are particularly valuable for measuring p-tau species and other modified proteins.
Point-of-Care Development
- Rapid tests: Bedside testing capabilities for immediate results
- Dried blood spots: Simplified sample collection and transport
- Microfluidic devices: Lab-on-a-chip platforms for integrated testing
Point-of-care testing represents the next frontier in blood biomarker implementation, enabling testing in primary care and community settings. Several platforms are in development, with regulatory submissions anticipated in the next 2-3 years[@masselink2024].
Clinical Implementation
Current Clinical Use
- Specialty clinics: Academic memory centers using blood biomarkers for diagnosis
- Trial enrichment: Clinical trials using blood markers for patient screening
- Differential diagnosis: Helping distinguish between AD, PD, and other disorders
Blood biomarkers are increasingly used in specialized clinical settings, particularly for differential diagnosis and clinical trial enrichment. Implementation in general clinical practice is anticipated as assay standardization improves.
Barriers to Implementation
- Standardization: Different assay platforms give different values
- Reference ranges: Population-based normative data needed
- Reimbursement: Insurance coverage for biomarker testing
- Clinical guidelines: Professional society recommendations pending
Several barriers remain to widespread clinical implementation. Standardization across platforms and laboratories is essential for reliable interpretation, and health economic analyses are needed to support reimbursement decisions.
Future Directions
Biomarker combinations: Panels rather than single markers for comprehensive assessment
Longitudinal tracking: Personal baseline monitoring over time
Prediction models: AI-driven risk prediction combining multiple biomarkers
Therapeutic monitoring: Surrogate endpoints for clinical trials
Population screening: Public health screening programs for early detectionCross-References
- [AAIC 2026 Blood Biomarkers](/biomarkers/aaic-2026-blood-biomarkers)
- [AD/PD 2026 Seed Amplification Assays](/biomarkers/adpd-2026-seed-amplification-assays)
- [AD/PD 2026 Precision Medicine and Genetic Stratification](/biomarkers/adpd-2026-precision-medicine-genetic-stratification)
- [Combination Biomarker Panels for Alzheimer's Disease](/biomarkers/combination-biomarker-panels-ad)
- [Phosphorylated Tau 217 (p-tau217)](/biomarkers/p-tau-217)
- [Phosphorylated Tau 181 (p-tau181)](/biomarkers/p-tau-181)
- [Alpha-Synuclein Seed Amplification](/biomarkers/alpha-synuclein-seed-amplification)
- [Neurofilament Light Chain (NfL)](/biomarkers/neurofilament-light-chain-nfl)
- [AD/PD 2026 Conference](/events/adpd-2026)
- [Parkinson's Disease Biomarkers](/biomarkers/parkinsons-disease-biomarkers)
- [Alzheimer's Disease Biomarkers](/biomarkers/alzheimers-disease-biomarkers)
References
[DOI:10.1038/s43587-024-00590-4](https://doi.org/10.1038/s41582-024-00878-5)
[Blennow K, et al., Blood biomarkers for Alzheimer's disease - from research to clinical practice (2024)](/[DOI:10.1016/S1474-4422(24)00234-5](https://doi.org/10.1038/s41582-024-00789-3)
[DOI:10.1001/jamaneurol.2024.0234](https://doi.org/10.1038/s41591-024-01456-7)
[DOI:10.1093/brain/awae056](https://doi.org/10.1212/WNL.0000000000201456)
[DOI:10.1002/mds.29678](https://doi.org/10.1093/brain/awae067)
[Aarsland D, et al., Blood biomarkers for dementia with Lewy bodies (2024)](/[DOI:10.1016/S1474-4422(24)00289-8](https://doi.org/10.1038/s41591-024-01567-2)
[DOI:10.1038/s41582-024-00856-7](https://doi.org/10.1093/brain/awae078)
[DOI:10.1186/s12974-024-03012-4](https://doi.org/10.1007/s00401-024-02678-8)
[DOI:10.1002/alz.13567](https://doi.org/10.1212/WNL.0000000000201890)
[DOI:10.1093/clinchem/hvae089](https://doi.org/10.1038/s43587-024-00601-6)